Inside This Issue

Posting of National PBM Documents May-July 2015
Posting of VAMedSAFE Documents May-July 2015
VHA Oncology Documents
Pharmacy-Prosthetics-Logistics and Acquisitions (PPL) Workgroup May-July 2015
National Contract Awards for CY 2015
PBM-MAP-VPE Webinars
Aug. 18th: Clinical Pharmacy Handbook
Sept. 15th: VA-DoD Lipid Guidelines
Anticoagulation TMS Programs

3 Prior Authorization Categories on the VANF
If any questions about Prior Authorization, please email to VHAPBH Prior Authorization National.
The recent issue of Ez Minutes can be read from your smart phone! Put the below link in your browser; hit search... and the current issue from the PBM INTERnet site will be ready to read. http://www.pbm.va.gov/PBM/EzMinutesCurrentCurrentEzMinutes.pdf
Don’t forget... you can also subscribe to Ez-Minutes and any documents posted to the What’s New Section on the PBM INTERnet website by subscribing to the RSS Feed. http://www.pbm.va.gov/PBMWeb/WhatsNew_at_PBM_RSS_Feed.xml

ADDED to the VA National Formulary (VANF)
- Abacavir/dolutegravir/lamivudine
- Amphotericin + dexamethasone, mixed amphotericin salts IR and SA forms (ADDERALL)
- Ciprofloxacin and dexamethasone Otic Suspension
- Darunavir/cobicistat
- Droxalmine [Restricted to women’s health]
- Phenylephrine
- Tbo-filotastim

Criteria for Use (CFU)
- Apremilast (In Psoriasis and Psoriatic Arthritis)
- Budesonide ER Tab
- C1 (Esterase) Inhibitor (recombinant) [Ecallantide, Icatibant for Hereditary Angioedema. Updated June 2015]
- Diltiazem [Updated June 2015]
- Inhaled Insulin
- Ivermectin 1% Cream
- Naloxegol
- Omalizumab [In Chronic Idiopathic or Spontaneous Urticaria]
- Ramucirumab
- Terfinumonide [Updated June 2015]

Abbreviated Review
- Integrase Inhibitor-based regimens: Abacavir/dolutegravir/lamivudine and Elvitegravir
- Cabozantinib
- Cobicistat
- Elvitegravir
- Fluticasone furoate
- HIV Protease-Inhibitors-based regimens: Darunavir/cobicistat, Atazanavir/cobicistat and Cobicistat
- Lenvatinib
- Umeclidinium Elipta
- Vandetanib

NOT ADDED to the National Formulary (VANF)
- Albendazole Chewable Tabs
- Apremilast [See CFU]
- Atazanavir/cobicistat
- Budesonide ER Tab [See CFU]
- C1 Esterase Inhibitor (recombinant)
- Cabozantinib
- Cholic Acid [Capsules, Oral]
- Cobicistat
- Dalbavancin
- Elvitegravir
- Fluticasone furoate
- Ivermectin [See CFU]
- Memantine ER + donepezil
- Metreloidin
- Naloxegol
- Omalizumab [See CFU]
- Oratnavinc
- Phenylephrine/Ketorolac Ophthalmic Injection
- Ramucirumab [See CFU]
- Sorafenib [In Differentiated Thyroid Carcinoma]
- Sotolatal Oral Solution
- Umeclidinium Elipta
- Vandetanib

Other Helpful Resources
- Determining Clinical Benefit of High Cost Oncology Drugs
- National Contract Awards CY2015
- Sotolatal Patient Information [Updated July 2015]
- Sotolatal Provider Information [Updated July 2015]

Clinical Recommendations
- Gram-Positive Recs for Use for Newer MRSA Agents [Updated June 2015]
- Naloxone Kits and Autoinjector [Updated June 2015]

Drug Monograph
- Apremilast
- C1 Inhibitor
- Collagenase Clostridium Histolyticum [Updated July 2015]
- Dalbavancin
- Inhaled Insulin
- Icatibant Monograph Addendum [data on angiotensin-converting enzyme inhibitor-induced angioedema (off-label use)]
- Icatibant [revise shelf life info only]
- Ivermectin 1% Cream
- Naloxegol [Updated July 2015]
- Oratnavinc
- Phenylephrine/Ketorolac Ophthalmic Injection
- Ramucirumab [Updated June 2015]
- Sorafenib [In Differentiated Thyroid Carcinoma]
- Tbo-filotastim

Posting of National PBM Documents May – July 2015
Formulary Decisions

Removed from the National Formulary (VANF)
- Chloral Hydrate (capsule and syrup-no longer marketed)
- Mebendazole (no longer marketed)
- Ofloxacin Otic Solution
- Thiabendazole (no longer marketed)

Click Here to Subscribe to the Ez Minutes

Watch for the next issue of Ez-Minutes Tuesday, November 3rd, 2015
VHA Oncology Guidance Documents

The VHA Oncology Guidance Document on Determining Clinical Benefit of High Cost Oncology Drugs was initially drafted by the High Cost Oncology Drug Workgroup, a collaboration of VA oncology providers and pharmacists. The purpose of the document is to guide members of the oncology health care team through a decision tree to help optimize patient outcomes while attempting to obtain the greatest value from innovator therapies. Within this document, the process of identifying the clinical benefit had been defined as obtaining improvement in any of the following outcomes: overall survival, progression-free survival, patient-related outcomes, and patient-related goals. As many drugs receive expedited FDA approval, these outcomes are often times not reached due to the shortened nature of the review process. Attempts to assign a net clinical benefit to these expedited drugs could miscommunicate their value to the field. To address this issue, the guidance document has been updated to address those drugs approved through an expedited process. In addition, the definition of “high cost drugs” has been updated to reflect recent literature. Go to the PBM website to review all the oncology documents! See the link below.


National Contract Awards for Calendar Year 2015

Click on this link to view the National Contract Awards CY 2015. [InTRAnet only]

Pharmacy-Prosthetics-Logistics (PPL)* Workgroup

The table below depicts the various products reviewed during Feb. 2015 meeting. The X marks which service(s) is responsible for managing the respective products. Please click HERE for previous recommendations and minutes made from earlier meetings.

<table>
<thead>
<tr>
<th>Products</th>
<th>Pharmacy+</th>
<th>Prosthetics+</th>
<th>Logistics+</th>
</tr>
</thead>
<tbody>
<tr>
<td>Actigraphy watches (assist in determining sleep patterns and circadian rhythms)</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antibiotic containing resorbable envelope used to stabilize cardiac device placement</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dental drills or kits used for dental implants</td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Donor bags for therapeutic phlebotomies</td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Esophageal or tracheal flange (replacement part for voice prosthesis)</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye drop assistive devices</td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Histatrol (positive histamine control)</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nebulizers</td>
<td>X (outpatients)</td>
<td>X (inpatients)</td>
<td></td>
</tr>
<tr>
<td>Neuro Stim system or military field stimulator (placed in clinic by provider)</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Punctal plugs</td>
<td>X (permanent)</td>
<td>X (dissolvable)</td>
<td></td>
</tr>
<tr>
<td>Replacement dental implants</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scrotal suspensory after surgery</td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Topical aerosol refrigerants</td>
<td>X (inpatient and clinic use)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tracheoesophageal puncture dilator for outpatients</td>
<td></td>
<td></td>
<td>X</td>
</tr>
</tbody>
</table>

*The PPL workgroup was created to help clarify the responsibility for management (e.g., ordering, storing, purchasing, and/or dispensing) of those products in which it is not clear which service should provide. The workgroup is not responsible for determining formulary status, clinical merit, or appropriate use of the products reviewed.

+Contingent upon approval from VISN or local Clinical Products Review Committee (CPRC). Implementation of these recommendations should be coordinated between services at local sites to ensure a smooth transition if recommendations lead to a change in responsible service. If you have any questions related to this announcement, please contact the responsible local service (Pharmacy, Prosthetics, or Logistics) for more detailed information.
NEW! Next PBM-MAP-VPE Webinar: August 18th, 2015 @ 3 PM ET

Transforming Clinical Pharmacy Practice:
Key Highlights from VHA Handbook 1108.11 Clinical Pharmacy Services

Links to VHA Handbook 1108.11 http://vaww.va.gov/vhapublications/ or http://www.va.gov/vhapublications/

No Accreditation. Come prepared with your questions!
Any questions, please contact Eric.Esplin@va.gov (EES) or Janet.Dailey@va.gov (PBM)

SAVE-THE-DATE: September 15th @ 3 PM ET

HEY PACT TEAMS and ALL PROVIDERS

Have you missed any of the VA-DoD Lipid Guidelines Webinars? Are you new to the VA and need to learn about the VA-DoD Lipid Guidelines? Do you need to learn how to utilize the VA-DoD Lipid Guidelines and apply them to your practice?

The PBM-MAP-VPE and the Employee Education System are pleased to bring the Lipid guideline webinar in September to a computer close to you:

“VA/DoD Dyslipidemia Guidelines for Cardiovascular Risk Reduction and Differences from the ACC/AHA Guidelines”

Objectives:
1. describe how the VA/DoD Guideline differs from the ACC/AHA 2013 Guideline;
2. list at least 2 key aspects of the VA/DoD Guideline; and
3. discuss the implications of the recently published IMPROVE-IT Trial

Accreditation: ACPE, ACCME, ACCME-NP
VANTS: 1-800-767-1750 Access Code 49792#

2015 Anticoagulation Revised TMS Programs are Available!

Basic Anticoagulation Program
https://www.tms.va.gov/learning/user/deeplink_redirect.jsp?linkId=ITEM_DETAILS&componentID=6720&componentTypeID=VA&revisionDate=127991670000
Accreditation: ACPE-T, ANCC, CDR, CA BRN for 3 years

Advanced Anticoagulation Program
https://www.tms.va.gov/learning/user/deeplink_redirect.jsp?linkId=ITEM_DETAILS&componentID=6719&componentTypeID=VA&revisionDate=127909920000
Accreditation: ACPE, ACCME, ACCME-NP for 3 years

Don’t Be Fooled….It’s not April 1st…The revision field inside TMS for both programs will depict 2010…..BUT the programs are the new and revised programs. (the field line can not be edited)
PBM is developing a 3 part webinar series on anticoagulation related topics later this year. Be sure to complete the Advanced Program in preparation. More details will be forthcoming.